Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention.
Fatma Nihan Akkoc MustafayevDiane D LiuAngelica M GutierrezJohn E LewisNuhad K IbrahimVicente ValeroDaniel J BooserJennifer K LittonKimberly KoenigDihua YuNour SneigeBanu K ArunPublished in: European journal of breast health (2023)
Dasatinib was well tolerated but did not induce any significant changes in serum biomarkers. The study could not fulfill its primary objective due to an inadequate number of paired FNA samples. Further, larger studies are needed to evaluate the effectiveness of Src inhibitors in breast cancer prevention.